Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with The VHL Alliance, the Large Urology Group Practice Association (LUGPA) and The National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

Supported by educational grants from AVEO Pharmaceuticals, Inc., Exelixis, and Novartis and Merck.

TUITION

Complimentary

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, October 29, 2021, at 10:30am – 11:30am EST
Friday, October 29, 2021, at 11:30am – 12:30pm EST

Enduring Material

October 29, 2021 – October 29, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Review recent advances in research and clinical trials in hereditary RCC
• Evaluate the clinical safety and efficacy data emerging for patients with VHL-associated RCC
• Integrate new and emerging evidence into adjuvant and frontline treatment regimens for advanced RCC
• Discuss advantages and disadvantages of current and emerging second- or third-line treatments for advanced RCC

TARGET AUDIENCE

The intended audience for this activity program are medical and genitourinary oncologists, urologists, nephrologists, nurse practitioners, physician assistants, and other members of the RCC treatment team.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com or www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Brian I. Rini, MD Chief of Clinical Trials, Ingram Professor of Medicine Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center	Consulting Fees (e.g., advisory boards): Aveo, BMS, Exelixis, Merck, and Pfizer Contracted Research: Aveo, BMS, Exelixis, Merck, and Pfizer
Eric Jonasch, MD Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences Division of Cancer Medicine Houston, TX	Consulting Fees (e.g., advisory boards): Aveo, Aravive, Calithera, Eisai, Exelixis, Ipsen, Merck, NiKang, Novartis, and Pfizer Contracted Research: Merck, Nikang, Novartis

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Tariqa Ackbarali Medical Director PlatformQ Health Education, LLC	None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com.com or ClinicalSeriesLive.com at 1-877-394-1306 or at Support@OMedLive.com.